When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CYCC - Cyclacel down 4% on sapacitabine/seliciclib data
Cyclacel Pharmaceuticals Inc.
Nano cap Cyclacel Pharmaceuticals (CYCC-3.9%) slips on average volume in response to results from a Phase 1 clinical trial evaluating a sequential regimen of sapacitabine and seliciclib in patients with BRCA-positive metastatic breast cancer. The data, apparently underwhelming to investors, were presented at AACR in Atlanta.
More news on: Cyclacel Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move,